Tebipenem Pivoxil NEW
| Price | $30 | $48 | $77 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-14 |
Product Details
| Product Name: Tebipenem Pivoxil | CAS No.: 161715-24-8 |
| Purity: 99.32% | Supply Ability: 10g |
| Release date: 2024/11/14 |
Product Introduction
Bioactivity
| 名稱 | Tebipenem Pivoxil |
| 描述 | Tebipenem Pivoxil (Orapenem) , an orally activity carbapenem antibiotic, is utilized in treating otolaryngologic and respiratory infections. |
| 體外活性 | Tebipenem Pivoxil has high?intestinal apical membrane permeability due to plural intestinal transport routes, including the uptake transporters such as OATP1A2 and OATP2B1 as well as simple diffusion. [1] Tebipenem Pivoxil is quickly converted to tebipenem?(TBPM), an active form of?Tebipenem Pivoxil. Tebipenem Pivoxil are absorbed quickly, and the bioavailability is 71.4%, 59.1%, 34.8% and 44.9%, respectively, in mouse, rat, dog and monkey. [2] Tebipenem shows the strongest bactericidal activity as early as 2 h after exposure at two times the MIC. Tebipenem shows higher affinities for PBP 1A and PBP 2B, high-molecular-weight enzymes, and for PBP 3, a low-molecular-weight enzyme, than for PBP 2X.?[3] Tebipenem?has a potent?activity?against?Neisseria gonorrhoeae; its?activity?is comparable to it of cefixime that has most potent activity among oral antibiotics. [4] |
| 體內(nèi)活性 | Tebipenem Pivoxil results in survival rate of 83%, compared with 25% survival for Amoxicillin and 0% survival for controls in animal model of?otitis?media. [5] Tebipenem?exhibits?slow?tight-binding inhibition at low micromolar concentrations versus the chromogenic?substrate?nitrocefin.?Tebipenem?acyl-enzyme complex remains stable for greater than 90 min and exists as mixture of the covalently bound drug and the bound retro-aldol cleavage product. [6] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : 81 mg/mL (162.8 mM) DMSO : 92 mg/mL (184.9 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| 關(guān)鍵字 | Antibiotic | broad antibacterial spectrum | L 084 | penicillin-binding protein | inhibit | L-084 | Inhibitor | orally active | ME-1211 | Haemophilus influenza | L084 | Bacterial | Tebipenem Pivoxil | Erythromycin-resistant Streptococcus pneumonia | Streptococcus pneumonia | ME 1211 |
| 相關(guān)產(chǎn)品 | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Kanamycin sulfate | G-418 disulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | EDTA copper(II) disodium salt | Dimethyl sulfoxide | Crystal Violet |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 內(nèi)質(zhì)網(wǎng)應(yīng)激化合物庫 | 上市藥物庫 | 兒童藥物庫 | 藥物功能重定位化合物庫 | 口服活性化合物庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 | 臨床前化合物庫 | 人代謝物化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $200.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-11-27 | ||
| $0.00/10g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-09-10 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $7.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-17 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY